PHIO - Phio Pharmaceuticals Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
78
138
15
19
34
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
34
Operating Expenses
Research Development
4,017
4,326
5,370
5,415
6,925
Selling General and Administrative
3,492
3,176
4,011
3,619
3,346
Total Operating Expenses
7,509
7,502
9,381
9,034
10,271
Operating Income or Loss
-7,431
-7,364
-9,366
-9,015
-10,237
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
57
4
-4,707
21
-2
Income Before Tax
-7,374
-7,360
-14,073
-8,994
-10,223
Income Tax Expense
-
0
-1,621
0
-
Income from Continuing Operations
-7,374
-7,360
-12,452
-8,994
-10,223
Net Income
-7,374
-7,360
-12,452
-8,994
-10,223
Net Income available to common shareholders
-7,374
-7,360
-12,452
-11,069
-10,432
Reported EPS
Basic
-
-1.04
-5.52
-16.40
-21.00
Diluted
-
-1.04
-5.52
-16.40
-21.00
Weighted average shares outstanding
Basic
-
7,045
2,258
675
497
Diluted
-
7,045
2,258
675
497
EBITDA
-
-7,283
-9,366
-9,015
-10,237